Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

KOJIMA Yuki (Depertment of Medical Oncology)



Dr. KOJIMA's story

As a physician scientist, I practice as a clinician, treating patients and conducting daily research for the development of cancer treatments. My research focuses on translational research in the areas of cancer biology and molecular therapeutics, and I have recently expanded my research to include projects with cancer genomics experts to explore the biological features of cancer. I am also actively engaged in the role of mentoring young researchers.

Research interests

Translational research

Professional Experiences

  • 2021-present Staff Physician, Department of Medical Oncology, National Cancer Center Hospital
  • 2020-2021 Physician Scientist, Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2017-2018 Resident, Department of Clinical Oncology, Aichi cancer center since
  • 2014-2017 Graduate student, Department of Hematology and Oncology, Nagoya University

Selected publications

  1. Nakamura IT, Ikegami M, Hasegawa N, Hayashi T, Ueno T, Kawazu M, Yagishita S, Goto Y, Shinno Y, Kojima Y, Takamochi K, Takahashi F, Takahashi K, Mano H, Kohsaka S. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. Cancer Sci. 2021 May;112(5):2006-2019.
  2. Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. Oncol Lett. 2020 Dec;20(6):336.
  3. Yamamoto H, Hayakawa F, Yasuda T, Odaira K, Minamikawa Y, Tange N, Hirano D, Kojima Y, Morishita T, Tsuzuki S, Naoe T, Kiyoi H. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities. FEBS Lett. 2019 Aug;593(16):2151-2161.
  4. Hirano D, Hayakawa F, Yasuda T, Tange N, Yamamoto H, Kojima Y, Morishita T, Imoto N, Tsuzuki S, Mano H, Naoe T, Kiyoi H. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity. Oncogene. 2019 Mar;38(13):2263-2274.
  5. Kojima Y, Hayakawa F, Morishita T, Sugimoto K, Minamikawa Y, Iwase M, Yamamoto H, Hirano D, Imoto N, Shimada K, Okada S, Kiyoi H. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. Pharmacol Res. 2017 Jun;120時24分2-251.
  6. Aoki T, Shimada K, Sakamoto A, Sugimoto K, Morishita T, Kojima Y, Shimada S, Kato S, Iriyama C, Kuno S, Harada Y, Tomita A, Hayakawa F, Kiyoi H. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget. 2017 Feb 21;8(8):13085-13098.
  7. Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget. 2016 Aug 30;7(35):56241-56252.
  8. Imoto N, Hayakawa F, Kurahashi S, Morishita T, Kojima Y, Yasuda T, Sugimoto K, Tsuzuki S, Naoe T, Kiyoi H. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia. J Biol Chem. 2016 Feb 26;291(9):4723-31.
  9. Kojima Y, Hagiwara S, Uehira T, Ajisawa A, Kitanaka A, Tanuma J, Okada S, Nagai H. Clinical Outcomes of AIDS-related Burkitt Lymphoma: A Multi-institution in Japan. Jpn J Clin Oncol. 2014 Apr;44(4):318-23
  10. Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. Cancer Chemother Pharmacol. 2012 9 70:391-397